TrialCancer2023

Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study.

Mahmut Gümüş et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.